114 related articles for article (PubMed ID: 6896222)
41. The relationship of thyroxine turnover to other parameters of peripheral thyroid function in Graves' disease.
Clifton-Bligh P; Burke G
J Lab Clin Med; 1975 Jun; 85(6):922-33. PubMed ID: 48532
[TBL] [Abstract][Full Text] [Related]
42. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
[TBL] [Abstract][Full Text] [Related]
43. Intentional radioiodine ablation in Graves' disease.
Wise PH; Burnet RB; Ahmad A; Harding PE
Lancet; 1975 Dec; 2(7947):1231-3. PubMed ID: 53722
[TBL] [Abstract][Full Text] [Related]
44. [Evaluation of radioiodine 131I treatment in Graves' disease patients with mild orbitopathy].
Bałdys-Waligórska A; Stefańska A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
Przegl Lek; 2009; 66(4):166-9. PubMed ID: 19708504
[TBL] [Abstract][Full Text] [Related]
45. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
[TBL] [Abstract][Full Text] [Related]
46. Transient hypothyroidism after iodine-131 therapy for Grave's disease.
Gómez N; Gómez JM; Orti A; Gavaldà L; Villabona C; Leyes P; Soler J
J Nucl Med; 1995 Sep; 36(9):1539-42. PubMed ID: 7658207
[TBL] [Abstract][Full Text] [Related]
47. [Radioiodine tretment of Graves' disease (author's transl)].
Konishi J; Kasagi K; Iida Y; Mori T; Torizuka K
Horumon To Rinsho; 1979 Nov; 27(11):1239-43. PubMed ID: 583264
[No Abstract] [Full Text] [Related]
48. Successful use of iodine and levothyroxine to treat Graves' disease in a pregnant patient with allergy to antithyroid drugs and high thyrotropin-binding inhibitor immunoglobulin after radioiodine therapy.
Kubota S; Ohye H; Sasaki I; Nishihara E; Kudo T; Fukata S; Amino N; Kuma K; Mitsuda N; Miyauchi A
Thyroid; 2005 Dec; 15(12):1373-6. PubMed ID: 16405411
[TBL] [Abstract][Full Text] [Related]
49. Relapse of Graves' disease 23 years after treatment with radioactive iodine (131I).
Hegele RA; Volpé R
J Clin Lab Immunol; 1985 Oct; 18(2):103-5. PubMed ID: 3841162
[TBL] [Abstract][Full Text] [Related]
50. [Variation of the thyrotropin-releasing-hormone (TRH) stimulated thyrotropin (TSH) response in comparison with the tyhroid-gland-suppression test and the triiodothyronine (T3) and thyroxine (T4) blood levels in the so-called euthyroid endocrine ophthalmopathy].
Wenzel KW
Endokrinologie; 1975 Sep; 66(1):67-73. PubMed ID: 1243821
[TBL] [Abstract][Full Text] [Related]
51. Anticlastogenic effect of Ginkgo biloba extract in Graves' disease patients receiving radioiodine therapy.
Dardano A; Ballardin M; Ferdeghini M; Lazzeri E; Traino C; Caraccio N; Mariani G; Barale R; Monzani F
J Clin Endocrinol Metab; 2007 Nov; 92(11):4286-9. PubMed ID: 17711926
[TBL] [Abstract][Full Text] [Related]
52. Free radicals and Graves' disease: the effects of therapy.
Wilson R; Chopra M; Bradley H; McKillop JH; Smith WE; Thomson JA
Clin Endocrinol (Oxf); 1989 Apr; 30(4):429-33. PubMed ID: 2598476
[TBL] [Abstract][Full Text] [Related]
53. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study.
Peters H; Fischer C; Bogner U; Reiners C; Schleusener H
Eur J Clin Invest; 1995 Mar; 25(3):186-93. PubMed ID: 7781666
[TBL] [Abstract][Full Text] [Related]
54. Thyrotropin-releasing hormone (a test to diagnose Graves' ophthalmopathy).
Hyman BN; Johnson PC
Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol; 1975; 79(3 Pt 2):OP524-8. PubMed ID: 50663
[No Abstract] [Full Text] [Related]
55. [Primary hypothyroidism as a possible cause of hypertension from long-term follow-up studies of patients with Graves' disease (author's transl)].
Okamura K; Inoue K; Shiroozu A; Nakashima T; Yoshinari M; Omae T; Yoshizumi T; Nishitani H
Nihon Naibunpi Gakkai Zasshi; 1980 Jun; 56(6):767-75. PubMed ID: 6893308
[TBL] [Abstract][Full Text] [Related]
56. Thionamides alter the efficacy of radioiodine treatment in patients with Graves' disease.
Koroscil TM
South Med J; 1995 Aug; 88(8):831-6. PubMed ID: 7631208
[TBL] [Abstract][Full Text] [Related]
57. Laboratory examination of the thyroid. 1. In vitro tests.
Schneider PB
Postgrad Med; 1974 Aug; 56(2):91-6. PubMed ID: 4136847
[No Abstract] [Full Text] [Related]
58. [Experience with the thyrotropin releasing hormone (TRH) test in the diagnosis of Graves' ophthalmopathy].
Otter R; Wiersinga WM; Peeters HF; Bleeker GM; Touber JL
Ned Tijdschr Geneeskd; 1982 Nov; 126(48):2189-93. PubMed ID: 6817147
[No Abstract] [Full Text] [Related]
59. [Radioiodine (I-131) treatment of Graves' disease (author's transl)].
Rösler H; Kinser J
Ther Umsch; 1973 Oct; 30(10):717-25. PubMed ID: 4800360
[No Abstract] [Full Text] [Related]
60. Interpretation of serum tri-iodothyronine levels measured by the sterling technic.
Wahner HW; Gorman CA
N Engl J Med; 1971 Feb; 284(5):225-30. PubMed ID: 4992676
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
